Scarica l'app Stockscreener
26.46
2.88%
0.74
Dopo l'orario di chiusura:
26.60
0.14
+0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$25.72
Aprire:
$26.25
Volume 24 ore:
3.81M
Relative Volume:
1.68
Capitalizzazione di mercato:
$2.61B
Reddito:
$669.43M
Utile/perdita netta:
$-609.36M
Rapporto P/E:
-4.3334
EPS:
-6.1061
Flusso di cassa netto:
$-507.20M
1 W Prestazione:
+3.81%
1M Prestazione:
-1.64%
6M Prestazione:
+15.50%
1 anno Prestazione:
-9.60%
Intervallo 1D:
$26.00
$26.91
Intervallo di 1 settimana:
$25.04
$28.50
Portata 52W:
$18.29
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
26.46 | 2.50B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | Goldman | Buy → Neutral |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy - Stocktwits
Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade) - Seeking Alpha
RARE Maintained by Morgan Stanley -- Price Target Raised to $74 - GuruFocus
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Morgan Stanley Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
How Investors May Respond To Ultragenyx Pharmaceutical (RARE) First FDA Accelerated Approval For GENGLYCOS - simplywall.st
182,638 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Blue Owl Capital Holdings LP - MarketBeat
RTW INVESTMENTS, LP Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shares Look 44% Undervalued on GF Value - GuruFocus
RARE Maintained by Canaccord Genuity -- Price Target Raised to $83 - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx scores FDA approval for gene therapy made at Bedford facility - The Business Journals
RARE Maintained by Citigroup -- Price Target Raised to $58.00 - GuruFocus
Citigroup Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease - MedCity News
Ultragenyx Shares Surge as FDA Grants First-Ever Approval for GSDIa Gene Therapy - finance.biggo.com
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing - PharmTech.com
RARE Maintained by Wells Fargo -- Price Target Raised to $46.00 - GuruFocus
Ultragenyx, after setbacks, nabs first gene therapy approval - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company - MarketBeat
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia - BioPharm International
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade - MarketBeat
Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa - pharmaphorum
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos - TradingView
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double - insights.citeline.com
Ultragenyx's new therapy targets patients with a rare genetic disease. It costs $2.7 million. - The Business Journals
H.C. Wainwright reiterates Ultragenyx stock rating at buy By Investing.com - Investing.com Nigeria
FDA approves Ultragenyx gene therapy - STAT
Canaccord raises Ultragenyx stock price target on FDA approval By Investing.com - Investing.com South Africa
Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock - Yahoo Finance
Ultragenyx Nabs FDA Nod for First Gene TherapyUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating at buy - Investing.com
Canaccord raises Ultragenyx stock price target on FDA approval - Investing.com
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy - Pharmaceutical Business review -
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy - MarketBeat
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $103 - GuruFocus
Ultragenyx’ Genglycos wins FDA accelerated approval - The Pharma Letter
FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia - AllSci
Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx stock surges on FDA gene therapy approval - Investing.com
Ultragenyx’s gene therapy wins first FDA approval for rare metabolic disorder - 101 WIXX
Ultragenyx Earnings Call Signals Record Sales, 2027 Pivot - TipRanks
Ultragenyx gets its first gene therapy over the regulatory finish line - FirstWord Pharma
RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher - Stocktwits
Ultragenyx receives FDA approval for gene therapy treating GSDIa By Investing.com - Investing.com Nigeria
Form 8K Ultragenyx For: 19 August By Investing.com - Investing.com South Africa
Ultragenyx stock surges on FDA gene therapy approval By Investing.com - Investing.com Australia
Ultragenyx’s gene therapy for rare metabolic disorder secures US FDA nod - 1470 & 100.3 WMBD
RARE Looks 41.8% Undervalued on GF Value™ After FDA Approval Boo - GuruFocus
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.07%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):